These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 26557805)

  • 1. Mechanisms of Cross-protection by Influenza Virus M2-based Vaccines.
    Lee YN; Kim MC; Lee YT; Kim YJ; Kang SM
    Immune Netw; 2015 Oct; 15(5):213-21. PubMed ID: 26557805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.
    Kim YJ; Kim KH; Ko EJ; Kim MC; Lee YN; Jung YJ; Lee YT; Kwon YM; Song JM; Kang SM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30068650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protection against homo and hetero-subtypic influenza A virus by optimized M2e DNA vaccine.
    Yao Y; Wang H; Chen J; Shao Z; He B; Chen J; Lan J; Chen Q; Chen Z
    Emerg Microbes Infect; 2019; 8(1):45-54. PubMed ID: 30866759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats.
    Wang W; Huang B; Wang X; Tan W; Ruan L
    Virol Sin; 2019 Oct; 34(5):583-591. PubMed ID: 31240620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.
    Kim YJ; Lee YT; Kim MC; Lee YN; Kim KH; Ko EJ; Song JM; Kang SM
    Front Immunol; 2017; 8():1730. PubMed ID: 29276514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses.
    Subbbiah J; Oh J; Kim KH; Shin CH; Park BR; Bhatnagar N; Jung YJ; Lee Y; Wang BZ; Seong BL; Kang SM
    Mol Ther Methods Clin Dev; 2022 Sep; 26():38-51. PubMed ID: 35755946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    Mooney AJ; Gabbard JD; Li Z; Dlugolenski DA; Johnson SK; Tripp RA; He B; Tompkins SM
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28931689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.
    Kim MC; Lee YN; Kim YJ; Choi HJ; Kim KH; Lee YJ; Kang SM
    Antiviral Res; 2017 Dec; 148():43-52. PubMed ID: 29107058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplementation of inactivated influenza vaccine with norovirus P particle-M2e chimeric vaccine enhances protection against heterologous virus challenge in chickens.
    Elaish M; Ngunjiri JM; Ali A; Xia M; Ibrahim M; Jang H; Hiremath J; Dhakal S; Helmy YA; Jiang X; Renukaradhya GJ; Lee CW
    PLoS One; 2017; 12(2):e0171174. PubMed ID: 28151964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterosubtypic protection against avian influenza virus by live attenuated and chimeric norovirus P-particle-M2e vaccines in chickens.
    Ghorbani A; Ngunjiri JM; Xia M; Elaish M; Jang H; Mahesh KC; Abundo MC; Jiang X; Lee CW
    Vaccine; 2019 Feb; 37(10):1356-1364. PubMed ID: 30691981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-Assembly M2e-Based Peptide Nanovaccine Confers Broad Protection Against Influenza Viruses.
    Wang Q; Zhang Y; Zou P; Wang M; Fu W; She J; Song Z; Xu J; Huang J; Wu F
    Front Microbiol; 2020; 11():1961. PubMed ID: 32922379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.
    Bimler L; Ronzulli SL; Song AY; Johnson SK; Jones CA; Kim T; Le DT; Tompkins SM; Paust S
    J Virol; 2021 Mar; 95(5):. PubMed ID: 33268521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
    Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
    Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens.
    Song BM; Kang HM; Lee EK; Jung SC; Kim MC; Lee YN; Kang SM; Lee YJ
    Vaccine; 2016 Jan; 34(5):678-686. PubMed ID: 26691568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.